SCHEMBL2018607

SCHEMBL2018607

c1cc2c3c(c1)c(-c1ccnc(N[C@H]4CCCNC4)n1)cn3CCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK7 P50613 1/20 0.48
CCNH P51946 1/20 0.48
MNAT1 P51948 1/20 0.48
CCNB2 O95067 3/20 0.46
CDK1 P06493 3/20 0.46
CCNB1 P14635 3/20 0.46
CCNB3 Q8WWL7 3/20 0.46
EGFR P00533 6/20 0.45
ERN1 O75460 9/20 0.44
MAPK10 P53779 3/20 0.43
RET P07949 1/20 0.43
KCNH2 Q12809 1/20 0.43
CDC7 O00311 1/20 0.43
PLK4 O00444 1/20 0.43
JAK2 O60674 1/20 0.43
MAP4K4 O95819 1/20 0.43
INSR P06213 1/20 0.43
CSF1R P07333 1/20 0.43
PIM1 P11309 1/20 0.43
PRKACA P17612 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12572739 0.80 CDC7 (0.47) CCNB2CDK1CCNB1CCNB3EGFR
Hydrochloric Acid SCHEMBL2021469 0.79 CDC7 (0.46) CCNB2CDK1CCNB1CCNB3EGFR
SCHEMBL12475277 0.74 EGFR (0.46) CCNB2CDK1CCNB1CCNB3EGFR
SCHEMBL17262018 0.74 HTR2A (0.44) EGFRKCNH2
SCHEMBL2021439 0.71 EGFR (0.47) CCNB2CDK1CCNB1CCNB3EGFR
SCHEMBL30687254 0.71 CCNT1 (0.74) CDK7CCNHMNAT1CCNB2CDK1
SCHEMBL23292393 0.70 MKNK1 (0.58) CDK7CCNHMNAT1MKNK2IRAK4
SCHEMBL2016080 0.70 EGFR (0.49) CCNB2CDK1CCNB1CCNB3EGFR
SCHEMBL2020150 0.70 EGFR (0.49) CCNB2CDK1CCNB1CCNB3EGFR
SCHEMBL22895795 0.69 CCNK (0.49) CDK7CCNHMNAT1CCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 CDK7 122/4885CCNH 38/4885MNAT1 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.